Eversept Partners, LP Sage Therapeutics, Inc. Transaction History

Eversept Partners, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$89.33 - $163.65 $738,848 - $1.35 Million	-8,271 Closed	0 $0
Q4 2018 Nov 08, 2023	SELL	$81.94 - $139.71 $2.9 Million - $4.94 Million	-35,350 Reduced 81.04%	8,271 $792,000
Q4 2018 Feb 13, 2019	SELL	$81.94 - $139.71 $2.9 Million - $4.94 Million	-35,350 Reduced 81.04%	8,271 $792,000
Q3 2018 Nov 08, 2023	BUY	$138.11 - $169.04 $30,384 - $37,188	220 Added 0.51%	43,621 $6.16 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $30,384 - $37,188	220 Added 0.51%	43,621 $6.16 Million
Q2 2018 Nov 08, 2023	BUY	$140.36 - $175.76 $2.72 Million - $3.41 Million	19,401 Added 80.84%	43,401 $6.79 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $2.72 Million - $3.41 Million	19,401 Added 80.84%	43,401 $6.79 Million
Q1 2018 Nov 08, 2023	BUY	$152.15 - $192.33 $3.65 Million - $4.62 Million	24,000 New	24,000 $3.87 Billion
Q1 2018 May 14, 2018	BUY	$152.15 - $192.33 $3.65 Million - $4.62 Million	24,000 New	24,000 $3.87 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.